Cargando…

A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells

BACKGROUND: Reversing multidrug resistance (MDR) has been an important goal for clinical and investigational oncologists. In the last few decades, significant effort has been made to search for inhibitors to reverse MDR by targeting ATP-binding cassette (ABC) transporters (Pgp, MRP) directly, but th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Duan, Zhenfeng, Zhang, Jianming, Ye, Shunan, Shen, Jacson, Choy, Edwin, Cote, Gregory, Harmon, David, Mankin, Henry, Hua, Yingqi, Zhang, Yu, Gray, Nathanael S, Hornicek, Francis J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4177239/ https://www.ncbi.nlm.nih.gov/pubmed/25236161 http://dx.doi.org/10.1186/1471-2407-14-681

Ejemplares similares

miR‐15b modulates multidrug resistance in human osteosarcoma in vitro and in vivo
por: Duan, Zhenfeng, et al.
Publicado: (2016)

Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells
por: Liao, Yunfei, et al.
Publicado: (2017)

Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2017)

Author Correction: Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11
por: Liao, Yunfei, et al.
Publicado: (2018)

CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma
por: Gao, Yan, et al.
Publicado: (2015)

Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
por: Shen, Jacson K., et al.
Publicado: (2016)

Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats
por: Gao, Yan, et al.
Publicado: (2016)

Expression of programmed cell death ligand 1 (PD-L1) and prevalence of tumor-infiltrating lymphocytes (TILs) in chordoma
por: Feng, Yong, et al.
Publicado: (2015)

Doxorubicin loaded Polymeric Nanoparticulate Delivery System to overcome drug resistance in osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2009)

Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Correction to: Transcriptional activation of CBFβ by CDK11(p110) is necessary to promote osteosarcoma cell proliferation
por: Feng, Yong, et al.
Publicado: (2019)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

ZNF93 Increases Resistance to ET-743 (Trabectedin; Yondelis®) and PM00104 (Zalypsis®) in Human Cancer Cell Lines
por: Duan, Zhenfeng, et al.
Publicado: (2009)

NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance
por: Duan, Zhenfeng, et al.
Publicado: (2009)

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells
por: Chen, Hua, et al.
Publicado: (2017)

Inhibition of ABCB1 (MDR1) Expression by an siRNA Nanoparticulate Delivery System to Overcome Drug Resistance in Osteosarcoma
por: Susa, Michiro, et al.
Publicado: (2010)

MicroRNA-155 expression is independently predictive of outcome in chordoma
por: Osaka, Eiji, et al.
Publicado: (2015)

Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma
por: Zhang, Linlin, et al.
Publicado: (2013)

Rhabdomyosarcoma: Advances in Molecular and Cellular Biology
por: Sun, Xin, et al.
Publicado: (2015)

Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance
por: Liu, Tang, et al.
Publicado: (2016)

Overexpression of EZH2 is associated with the poor prognosis in osteosarcoma and function analysis indicates a therapeutic potential
por: Sun, Ranran, et al.
Publicado: (2016)

Synergistic Effects of Targeted PI3K Signaling Inhibition and Chemotherapy in Liposarcoma
por: Guo, Shang, et al.
Publicado: (2014)

MicroRNA Involvement in Osteosarcoma
por: Kobayashi, Eisuke, et al.
Publicado: (2012)

MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer
por: Yang, Xiaoqian, et al.
Publicado: (2015)

Polymeric nanoparticle-based delivery of microRNA-199a-3p inhibits proliferation and growth of osteosarcoma cells
por: Zhang, Linlin, et al.
Publicado: (2015)

Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer
por: Gao, Yan, et al.
Publicado: (2015)

Genotyping Cancer-Associated Genes in Chordoma Identifies Mutations in Oncogenes and Areas of Chromosomal Loss Involving CDKN2A, PTEN, and SMARCB1
por: Choy, Edwin, et al.
Publicado: (2014)

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer
por: Zhou, Yubing, et al.
Publicado: (2016)

Noncoding RNA in drug resistant sarcoma
por: Li, Xiaoyang, et al.
Publicado: (2017)

Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma
por: Liu, Pei, et al.
Publicado: (2017)

The role of extracelluar matrix in osteosarcoma progression and metastasis
por: Cui, Juncheng, et al.
Publicado: (2020)

Extraskeletal osteosarcoma: A large series treated at a single institution
por: Wang, Haotong, et al.
Publicado: (2018)

Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma
por: Li, Xiaoyang, et al.
Publicado: (2020)

SMARCB1 expression is a novel diagnostic and prognostic biomarker for osteosarcoma
por: Guo, Tao, et al.
Publicado: (2022)

Expression and Clinical Significance of High‐Mobility Group AT‐hook 2 (HMGA2) in Osteosarcoma
por: Cui, Juncheng, et al.
Publicado: (2022)

Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2018)

Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy
por: Li, Yongshuang, et al.
Publicado: (2020)

Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma
por: Ma, Hangzhan, et al.
Publicado: (2021)

Development of a new pre-vascularized tissue-engineered construct using pre-differentiated rADSCs, arteriovenous vascular bundle and porous nano-hydroxyapatide-polyamide 66 scaffold
por: Yang, Pei, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lhfhu1jd2p994bt2lpbgjh3dou